
    
      Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19
      Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies(including
      B-cell Acute lymphoblastic Leukemia、B-cell Chronic Lymphocytic Leukemia、Non-Hodgkin's
      lymphoma) and Determine the Best Dosage.
    
  